INBX NASDAQ
Inhibrx Biosciences Inc.
1W: -2.6%
1M: -22.4%
3M: -0.1%
YTD: +29.2%
1Y: +185.4%
$96.99
-0.94 (-0.96%)
Weekly Expected Move ±7.5%
$82
$90
$97
$104
$112
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$5.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range28.16-155.29
Volume201,446
Avg Volume315,452
Beta3.67
Dividend—
Analyst Ratings
Company Info
CEOMark Lappe
Employees110
SectorHealthcare
IndustryBiotechnology
IPO Date2024-05-29
Websiteinhibrx.com
11025 North Torrey Pines Road
La Jolla, CA 92037
US
La Jolla, CA 92037
US
858-795-4220
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Latest News
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Bank of America Corp DE Makes New $79.70 Million Investment in Inhibrx Biosciences, Inc. $INBX
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx, Eikon rise after insider buying
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lappe Mark | P-Purchase | 1,500 | $98.88 | 2026-09-28 |
| Lappe Mark | P-Purchase | 3,000 | $101.70 | 2026-09-28 |
| Lappe Mark | P-Purchase | 3,324 | $98.87 | 2026-09-25 |
| Lappe Mark | P-Purchase | 2,176 | $99.60 | 2026-09-25 |
| Kayyem Jon Faiz | P-Purchase | 5,000 | $100.00 | 2026-09-23 |